Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
Stocks · News reference
Arcutis Biotherapeutics shares are trading higher after Cantor Fitzgerald initiated its coverage on the stock with an Overweight rating and announced a price target of $48.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
Arcutis Biotherapeutics presented clinical data for ZORYVE (roflumilast) across multiple inflammatory skin conditions at major dermatology conferences. The INTEGUMENT-INFANT trial showed the drug was well-tolerated in infants aged 3-24 months with atopic dermatitis, with 34.4% achieving disease clearance at 4 weeks. Additional analyses demonstrated ZORYVE's efficacy in treating psoriasis on special sites including the scalp and genitals, with improvements in sexual function and quality of life. Real-world research highlighted concerns about long-term topical corticosteroid use, including skin thinning and systemic side effects, positioning ZORYVE as a potential alternative therapy.